Shots:

• Sorrento will provide manufacturing support to Celularity as it intends to commence the P-I/II clinical study of CYNK-001 in 89 adults with COVID-19.
• The addition of Sorrento’s cGMP cell therapy manufacturing capacity is expected to accelerate the rapid scale-up and sustained production of Celularity’s CYNK-001 to be used in its P-I/II study in COVID-19 infected patients along with its existing clinical programs in AML- MM- and GBM
• Celularity is planning to launch CYNK-001 manufacturing at its new purpose-built cGMP/cGTP manufacturing facility in Florham Park- New Jersey

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: Sorrento